What Theralase Technologies does

Theralase Technologies Inc. is a Toronto-based, TSX Venture Exchange-listed (TSXV: TLT) clinical-stage biopharmaceutical company founded in 1995 that operates two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The ACT division develops patented light-activated Photo Dynamic Compounds (PDCs) — most notably lead asset TLD-1433 (marketed as Ruvidar), and TLD-1433 bonded with transferrin (marketed as Rutherrin) — which are activated by proprietary medical laser systems (TLC-3200 for intravesical bladder cancer delivery) to produce reactive oxygen species that destroy cancer cells. The lead program is in a Phase II clinical study for BCG-unresponsive Non-Muscle Invasive Bladder Cancer, with reported 65.2% complete response rate across 89 evaluable patients, FDA Fast Track Designation, and planned New Drug Application submissions to Health Canada and the FDA under rolling review in Q3 2026.

The CLT division designs, manufactures, and sells therapeutic medical laser systems — including the TLC-2000 Series (with SMART technology for adjustable energy density), TLC-100, TLC-300, TLC-900, and TLC-2100 — that use dual-wavelength superpulsed laser technology (660nm visible red and 905nm near infrared) to activate cellular pathways for pain relief, inflammation reduction, and tissue healing. These are sold directly to a fragmented base of healthcare practitioners (chiropractors, physiotherapists, naturopaths, dentists), veterinary clinics, and equine specialists via a quote-based pricing model, supported by a clinic locator tool that drives patient referrals.

Theralase's business model is bifurcated: hardware sales generate modest commercial revenue (FY2025: $816,468, down 21% YoY; Q1 2026: $132,634, up 45% YoY with margins expanding from 15% to 49%), while the oncology pipeline is funded through a series of private placements and a May 2026 brokered LIFE financing totaling over C$8.9M raised between 2022 and 2026, with consistent insider participation. Strategic positioning rests on 42 issued patents and 23 pending applications, FDA Fast Track Designation, FDA 510(k) and Health Canada clearances for the laser systems, and a January 2026 combination therapy development agreement with Ferring Pharmaceuticals pairing Ruvidar with Adstiladrin for high-risk NMIBC.

Name

Theralase Technologies

Legal name

Theralase Technologies Inc.

Website

https://theralase.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Theralase Technologies is a clinical-stage biopharmaceutical company developing light-activated Photo Dynamic Compounds (Ruvidar, Rutherrin) for bladder cancer and dual-wavelength therapeutic laser systems for pain management, serving healthcare practitioners, veterinarians, and oncology clinical trial sites in North America.

Ownership category

akta.pro rank

Product category

Medical Laser Systems

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Urologic Oncology (HLAKAOAB)

Keywords

• Photodynamic cancer therapy
• Medical laser systems
• Therapeutic laser devices
• Bladder cancer treatment
• Pain management technology

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Laser Hardware Sales: Theralase designs, manufactures, and sells therapeutic laser systems including the TLC-2000 Series, TLC-100, TLC-300, and TLC-900. These are sold directly to healthcare practitioners including chiropractors, physiotherapists, naturopaths, veterinarians, and other clinical professionals. Pricing is quote-based with various configurations available.
2. Clinical Development and Research: The company conducts clinical trials for its Anti-Cancer Therapy division, funded through private placements and financing. Revenue is not yet commercialized from this stream; the company is in Phase II clinical stage for bladder cancer treatment.
3. Clinical Training and Support Services: Theralase provides clinical training programs, customer support, and technical services to practitioners using their laser systems. The company offers annual or unlimited product warranties, software updates, and marketing support to customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Theralase Technologies operates two divisions: (1) Anti-Cancer Therapy (ACT), which develops patented light-activated Photo Dynamic Compounds (PDCs) — lead compounds Ruvidar (TLD-1433) and Rutherrin — that destroy cancer cells when activated by proprietary medical laser systems; (2) Cool Laser Therapy (CLT), which designs, manufactures and sells FDA- and Health Canada-cleared dual-wavelength superpulsed therapeutic laser systems (TLC-2000, TLC-100, TLC-300, TLC-900) for healthcare practitioners to treat pain, inflammation and tissue injuries in humans and animals.

Product overview

Theralase Technologies operates two main divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The ACT division develops patented light-activated Photo Dynamic Compounds (PDCs) including Ruvidar (TLD-1433) for bladder cancer treatment and Rutherrin for lung cancer, activated by proprietary medical laser systems (TLC-3200). The CLT division manufactures therapeutic laser systems including the TLC-2000 Series (SMART laser technology), TLC-100, TLC-300, TLC-900 controller-less systems, and TLC-2100 configurations, all using dual-wavelength superpulsed laser technology (660nm and 905nm) for pain treatment. Both divisions are designed, developed, and manufactured by Theralase for medical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• TLC-2000 Series Industry-leading SMART therapeutic laser system combining 660nm visible red and 905nm superpulsed near-infrared laser diodes to activate all three cellular pathways (pain elimination, inflammation reduction, accelerated healing); FDA and Health Canada cleared for knee pain treatment, with full controller, multiple probe options, tablet control and customizable protocols. Sold to chiropractors, physiotherapists, naturopaths, dentists, veterinarians and other clinical professionals.
• TLC-100 Controller-less Laser Entry-level, portable controller-less therapeutic laser with a single 905nm near-infrared probe for small-area treatment of nerve, muscle and joint conditions. Targeted at smaller or budget-conscious practices.
• TLC-300 Controller-less Laser Portable triple-probe controller-less laser system with 1x905nm near-infrared and 2x660nm visible red emitters covering a 3 cm² area, with internal battery for up to one hour of cordless treatment.
• TLC-900 Controller-less Laser High-power controller-less multi-probe therapeutic laser combining 5x905nm near-infrared and 4x660nm visible red lasers covering a 20 cm² area, available in four power levels for larger treatment zones.
• TLC-3200 Medical Laser System Specialized medical laser system designed for intravesical light activation of TLD-1433 (Ruvidar) during treatment of BCG-unresponsive Non-Muscle Invasive Bladder Cancer; upgraded based on Phase Ib clinical feedback. Used as part of the drug-device combination in Theralase's Phase II NMIBC clinical program.
• Ruvidar (TLD-1433) Lead light-activated Photo Dynamic Compound (a ruthenium-based coordination complex) for treatment of BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ; administered intravesically and activated by the TLC-3200 laser to produce singlet oxygen and reactive oxygen species that destroy cancer cells. Currently in Phase II clinical trials.
• Rutherrin Photodynamic compound consisting of TLD-1433 bonded with transferrin to form a targeted oncology drug; uses transferrin receptor-mediated uptake to preferentially deliver the PDC to cancer cells, including in preclinical Non-Small Cell Lung Cancer (NSCLC) models.

Quantifiable outcome

• 65.2% complete response rate in BCG-unresponsive NMIBC patients (58/89 evaluable patients)
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Ferring PharmaceuticalscoreStrategic or Co-development Partner · 9 January 2026Collaborative clinical development agreement to investigate combination therapy of Theralase's Ruvidar with Ferring's FDA-approved Adstiladrin (intravesical gene therapy) for high-risk BCG-unresponsive non-muscle invasive bladder cancer. A new cohort will be added to Theralase's existing clinical program (NCT03945162), with enrollment planned in the US first with potential expansion to Canada.
• University Health Network (UHN)coreStrategic or Co-development PartnerResearch partnership with UHN including Princess Margaret Cancer Centre for clinical research and development of Anti-Cancer Therapy. UHN Research Ethics Board approved commencement of Phase II NMIBC clinical study.
• McGill University Health CentreminorStrategic or Co-development PartnerResearch and clinical partnership for advancing photodynamic therapy research and development.
• University of British ColumbiaminorStrategic or Co-development PartnerAcademic partnership for research collaboration in cancer treatment and laser therapy development.
• London Health Sciences FoundationminorStrategic or Co-development PartnerHealthcare foundation partnership supporting clinical research initiatives.
• Carolina Urologic Research CenterminorImplementation/ SI/ Consulting PartnerClinical trial site partner for Phase II NMIBC clinical study, one of 12 sites across Canada and the US.
• Urology Associates (Nashville)minorImplementation/ SI/ Consulting PartnerClinical trial site partner for Phase II NMIBC clinical study participation.
• Urology of IndianaminorImplementation/ SI/ Consulting PartnerClinical trial site partner for bladder cancer clinical research.
• Central Ohio Urology GroupminorImplementation/ SI/ Consulting PartnerClinical trial site partner for Phase II clinical study participation.
• St. Joseph's Healthcare HamiltonminorImplementation/ SI/ Consulting PartnerCanadian clinical trial site partner for NMIBC clinical study.
• Associated Medical Professionals (NY)minorImplementation/ SI/ Consulting PartnerUS clinical trial site partner for bladder cancer clinical research.
• Nova Scotia Health AuthorityminorImplementation/ SI/ Consulting PartnerCanadian healthcare authority partnership for clinical research collaboration.
• University of ChicagominorStrategic or Co-development PartnerAcademic research partnership for photodynamic therapy development.
• JSS Medical ResearchminorImplementation/ SI/ Consulting PartnerMontreal-based CRO partnership established in 2014 for clinical development and regulatory submission support for bladder cancer treatment.
• SAFC (Sigma-Aldrich Corporation)minorOEM/ Whitelabel/ Licensing PartnerPartnership with Sigma-Aldrich's custom manufacturing services division for manufacture of anti-cancer drug compounds.
• TMX Equity Transfer Services Inc.minorOthersTransfer agent services for share registry management, located at 100 Adelaide Street West, Suite 301, Toronto, Ontario.
• AGT Partners LLPminorOthersExternal auditor for financial statement audits, located in Woodbridge, Ontario.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Photocure ASA: Norwegian specialty pharma commercializing Hexvix/Cysview, a photodynamic compound for bladder cancer detection. Directly comparable as a PDT-focused company in urologic oncology with both drug and device components.
• Biofrontera AG: German biopharma commercializing prescription PDT treatments (Ameluz) combined with light sources. Comparable as a PDT specialty company developing light-activated pharmaceutical therapies with proprietary drug-device combinations.
• Asieris MediTech: Clinical-stage Chinese biotech focused on urologic oncology therapeutics, including drugs for BCG-unresponsive NMIBC. Directly comparable target indication, stage, and therapeutic approach to Theralase's ACT division.
• Aspen Laser Systems: US-based manufacturer of FDA-cleared therapeutic cold laser systems for pain management and rehabilitation. Closely comparable as a direct competitor in the same Cool Laser Therapy / LLLT practitioner market segment.
• LiteCure: US manufacturer of Class IV therapeutic lasers (LightForce) used in physical therapy and sports medicine. Direct competitor in the practitioner-grade pain-management laser segment Theralase serves.
• Multi Radiance Medical: Manufacturer of FDA-cleared therapeutic super pulsed laser devices for pain relief and tissue healing in clinical practice. Direct competitor in the same laser therapy practitioner channel.

Broad incumbents

• Lumenis (Boston Scientific): Lumenis, now part of Boston Scientific, is a global leader in surgical and aesthetic medical lasers. Comparable as a broad incumbent offering overlapping laser system capabilities for medical and aesthetic procedures.
• Cynosure (Hologic): Global medical aesthetic laser systems manufacturer, now owned by Hologic. Comparable as a broad incumbent offering laser platforms serving physicians across multiple specialties including pain management and dermatology.
• Encompass Health/DJO (Enovis): Major orthopedic and rehabilitation device company (Chattanooga brand) offering therapeutic laser, ultrasound, and electrotherapy systems. Comparable as a broad incumbent in the practitioner channel for non-invasive pain management equipment.

Others

• Ferring Pharmaceuticals: Swiss specialty pharma and partner to Theralase for the Ruvidar + Adstiladrin combination study. Comparable as a strategic ecosystem participant in urologic oncology and Theralase's most important commercial validation partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/TheralaseTechnologies
• LinkedInlinkedin.com/company/theralase-technologies-inc-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds18 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theralase Technologies